Beleaguered Canadian drugmaker Valeant Pharmaceuticals International filed its long-delayed annual report on Friday, in which it identified misstatements that would reduce some of its previously reported revenue.
Valeant said it was in compliance with its credit agreement and senior note indentures and that no additional restatements were required beyond those previously disclosed.
The filing of the report will help the company stave off a possible default on its $30 billion debt.
The company had said it would file the report by April 29, although it had an extension agreement with its creditors to delay the filing until June 11.
The Laval, Quebec-based company's U.S-listed stock fell about 2 percent in premarket trade.